Treprostinil is a synthetic prostacyclin analog primarily used to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
It is a prostacyclin analog with vasodilator, anti-inflammatory, and anti-fibrotic properties.
It works by relaxing narrowed blood vessels in the lungs, lowering pulmonary pressure, and preventing blood clots, which ultimately reduces the workload on the heart.
Ot is available in multiple formulations to suit different stages and severities of the disease:
Inhaled (Tyvaso, Tyvaso DPI, Yutrepia): Delivered as a nebulized solution or dry powder directly to the lungs, typically used three to four times a day.
Infusion (Remodulin,): Administered continuously through a subcutaneous (under the skin) or intravenous (IV) pump.
Oral (Orenitram): Extended-release tablets taken with food, usually two to three times a day.
Mechanism of Action: as a prostacyclin analog, treprostinil directly promotes vasodilation of both systemic and pulmonary arterial vascular beds.
It also acts as a potent inhibitor of platelet aggregation.
This dual-action improves cardiac output, decreases pulmonary resistance, and helps alleviate exercise-associated shortness of breath.
Side effects vary depending on the route of administration, but generally include:Infusion site pain or reactions: Very common (up to 85%) for those using subcutaneous pumps.
37% of patients discontinue treatment prematurely with approximately 19% discontinuing treatment, owing two adverse events, with cough being the most common reason.
Systemic effects: Headache, flushing, nausea, diarrhea, and jaw pain.
Bleeding risks: Because it inhibits platelet aggregation, it increases the risk of bleeding, particularly in patients taking anticoagulants like warfarin.
Patients should not abruptly stop taking treprostinil without medical supervision, as it can cause a dangerous rebound of pulmonary hypertension symptoms.
In patients with IPF, inhaled treprostinil was associated with a small decline in FVC, and fewer clinical worsening events than placebo over a period of 52 weeks.